Core Viewpoint - Kezar Life Sciences has agreed to be acquired by Aurinia Pharmaceuticals amid ongoing financial difficulties, with the deal structured to provide cash and contingent value rights to shareholders [1][2]. Acquisition Details - The acquisition agreement, announced on March 30, 2026, stipulates that Kezar shareholders will receive $6.95 in cash per share plus one non-transferable contingent value right (CVR) [2]. - The transaction will be executed as a tender offer expected to launch by April 13, 2026, followed by a merger, contingent on several conditions including a majority of outstanding shares being tendered and Kezar having at least $50 million in closing net cash [2]. - The deal is anticipated to close in the second quarter of 2026 and has received unanimous approval from Kezar's board, supported by key investor Tang Capital Partners [2]. Shareholder Investigations - Law firms Ademi LLP and Halper Sadeh LLC are investigating the acquisition to determine if Kezar's board breached fiduciary duties and whether the best possible price was obtained for shareholders [3]. Financial Performance - For the year ended December 31, 2025, Kezar reported a net loss of approximately $56.0 million, an improvement from $83.7 million in 2024, with an operating loss of $59.1 million [4]. - In Q4 2025, Kezar posted an EPS of -$1.99, missing analyst consensus estimates of around -$1.39, and the company has no commercial revenue [4]. - Kezar maintains a cash runway supported by prior cost-cutting measures, including workforce reductions, and held substantial cash reserves previously reported in the $70–90 million range [4][5]. Market Reaction and Strategic Context - Following the acquisition announcement, KZR shares surged approximately 19–21%, trading around $7.45, reflecting a premium to the $6.95 cash offer due to CVR value and deal uncertainty [6]. - The acquisition allows Aurinia to expand its autoimmune disease portfolio by adding zetomipzomib, which has shown promising clinical data and positive FDA interactions [6]. Additional Provisions - The agreement includes provisions that may deter or penalize competing offers, a common feature in such transactions [7]. - The CVR may provide additional payments tied to ongoing clinical development of Kezar's lead candidate zetomipzomib and other financial arrangements [8].

Core Viewpoint - Ademi LLP is investigating Kezar Life Sciences, Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Aurinia, focusing on whether shareholders are receiving a fair price [1][4]. Transaction Details - In the announced transaction, Kezar stockholders will receive $6.955 in cash per share along with one contingent value right (CVR) [3]. - The CVR includes rights to potential payments from the clinical development of zetomipzomib, proceeds from Kezar's collaboration with Everest Medicines, and the sale of its Sec61-based program to Enodia Therapeutics, as well as 100% of Kezar's closing net cash exceeding $50 million, net of certain expenses [3]. Board Conduct Investigation - The transaction agreement imposes significant penalties on Kezar for accepting competing bids, which raises concerns about the board's fulfillment of fiduciary duties to all shareholders [4]. - Ademi LLP specializes in shareholder litigation involving buyouts, mergers, and individual shareholder rights, indicating a focus on protecting shareholder interests [4].

Core Viewpoint - Kezar Life Sciences has received a Type C meeting from the FDA to discuss the development of zetomipzomib for autoimmune hepatitis, indicating progress in its clinical development and potential for addressing unmet medical needs in this area [1][2][3] Group 1: Company Overview - Kezar Life Sciences is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases [4] - Zetomipzomib is a selective immunoproteasome inhibitor being evaluated for autoimmune hepatitis and has potential applications in multiple chronic immune-mediated diseases [5] Group 2: Clinical Development - The Type C meeting will review a proposed global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory autoimmune hepatitis [2] - Kezar submitted pharmacokinetic and hepatic safety data from previous trials to support its proposal for parallel studies in autoimmune hepatitis and hepatic impairment [2] Group 3: Market Need - Autoimmune hepatitis is a rare chronic disease affecting approximately 100,000 individuals in the U.S., with a significant unmet medical need for effective treatments [6] - Current standard treatments involve chronic immunosuppressive therapies that can lead to severe side effects, highlighting the need for alternatives that minimize or eliminate the use of corticosteroids [6] Group 4: Strategic Initiatives - The company is undergoing a strategic review process to maximize shareholder value, which includes workforce reductions and cost-containment measures [3] - Kezar has engaged TD Cowen to assist in this strategic review, indicating a focus on enhancing shareholder returns [3]

Zetomipzomib in Autoimmune Hepatitis (AIH) - The PORTOLA Phase 2 study evaluated zetomipzomib in AIH patients with relapsed disease or inadequate response to prior therapy [16] - In a pre-specified subgroup of patients on steroid-based therapy (n=21), 36% (5/14) of zetomipzomib-treated patients achieved a steroid-sparing complete biochemical remission (CR) by Week 24, compared to 0% (0/7) in the placebo arm [18] - In the Intent to Treat (ITT) population (n=24), 31.3% (5/16) of zetomipzomib-treated patients achieved a steroid-sparing CR by Week 24 versus 12.5% (1/8) in the placebo arm [18] - The PORTOLA results support a registrational program in AIH, a disease affecting approximately 100,000 patients in the US [17, 21] - The company plans to present PORTOLA results at a major medical conference in the second half of 2025 [43] Zetomipzomib in Lupus Nephritis (LN) - In the MISSION Phase 2 study, 35% of LN patients achieved a complete renal response (CRR) following 25 weeks of treatment without induction therapy [48, 50] - In the PALIZADE Phase 2 study, over 40% of patients achieved a UPCR ≤0.5 at Week 25 in the 60 mg zetomipzomib dose group [48] - The MISSION Phase 2 study showed an 83% median reduction in UPCR from baseline to Week 29 (4 weeks post-EOT) [50] - In the PALIZADE trial, the median percent change in UPCR from baseline at Week 25 was -67% in the Zetomipzomib 60mg group [54] Safety and Tolerability - In the PORTOLA study, the most common treatment emergent adverse events (TEAEs) were injection site reactions (ISRs) and systemic injection reactions (SIRs), all of which were Grade 1 or Grade 2 [18]